Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.16155
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

International Journal of Hematology
Hematology
2020English

Advancing Chimeric Antigen Receptor T Cell Therapy With CRISPR/Cas9

Protein & Cell
BiochemistryBiotechnologyDrug DiscoveryCell BiologyMedicine
2017English

Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Immunotherapy
OncologyAllergyImmunology
2016English

169. Clinically Adaptable CD19-Specific Chimeric Antigen Receptor

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy